An October equity offering raised approximately $514 million (with net proceeds of $576 million), but investors who were diluted by the move didn't like that the offering was priced 11% below where the stock had been trading. Its just released Q3 report also showed a much wider-than-expected loss of $0.48 per share compared to consensus estimates of $0.19, highlighting investor concerns over ongoing cash burn and delayed profitability.
For a safer wager, you might just buy and hold Tesla ( NASDAQ:TSLA) stock since it's a well-known and widely analyzed company with a stake in the self-driving car market. On the other hand, Aurora Innovation stock is low-priced and under the radar, so it has the potential to explode higher. On the other hand, a recently released financial filing should remind investors that Aurora Innovation is still a "show-me" story.
Shares of Tylenol maker Kenvue bounced back sharply at the opening bell Tuesday, a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines, and autism. "Don't take Tylenol," Trump instructed pregnant women around a dozen times during the White House news conference Monday, also urging mothers not to give their infants the drug, known by the generic name acetaminophen in the U.S. or paracetamol in most other countries.
Conservative investors might prefer to own shares of traditional insurance companies like Allstate ( NYSE:ALL) and Progressive ( NYSE:PGR), and that's fine. However, if you're more adventurous, you might choose to look into modern disrupters like Lemonade ( NYSE:LMND), Trupanion ( NASDAQ:TRUP), Hippo ( NYSE:HIPO), and the subject of today's analysis, Root, Inc. ( NASDAQ:ROOT). There are risks to investing in high-tech insurance plays, but the potential rewards could be substantial.